Gaps Between Guidelines and Clinical Practice on Implementing De-escalation of Thyroid Hormone Suppression in Thyroid Cancer Patients

Abstract

Get full access to this article

View all access options for this article.

References

Ringel

, Sosa

, Baloch

, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025; 35(8):841-985; doi: 10.1177/10507256251363120.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Thyroid carcinoma. Version 1.2025. 2025. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470.

Papaleontiou

, Chen

, Banerjee

, et al. Thyrotropin suppression for papillary thyroid cancer: A physician survey study. Thyroid, 2021; 31(9):1383-1390; doi: 10.1089/thy.2021.0033.

Francis-Levin

, Tan

, Gay

, et al. A qualitative study of clinician barriers and facilitators to de-escalation of thyroid stimulating hormone suppression in thyroid cancer survivors. Endocr Pract, 2025; doi: 10.1016/j.eprac.2025.12.009.

Petranović Ovčariček

, Campennì

, D’Aurizio

, et al. When guidelines meet reality: The combined impact of assay variability and prescribing differences on TSH management in thyroid cancer. Cancers, 2025; 17(24); doi: 10.3390/cancers17243912.

Thewjitcharoen

, Chatchomchuan

, Wanothayaroj

, et al. Clinical inertia in thyrotropin suppressive therapy for low-risk differentiated thyroid cancer: A real-world experience at an endocrine center in Bangkok. Medicine (Baltimore), 2024; 103(21):e38290; doi: 10.1097/MD.0000000000038290.